256 chapter 2 Table 62. Baseline characteristics of included studies investigating [18F]FDG-PET reference country study design ntot ni femalei agei, y TN sizei, mm Kresnik 2003 Austria n.s. 43 35 80% 25-84 6-80 Mitchell 2005 USA n.s. 48 24 n.s. n.s. n.s. de Geus-Oei 2006 Netherlands PS multicenter 44 42 93% 22-77 n.s. Kim 2007 South Korea n.s. 46 36 85% 44 ±13 12-90 Sebastianes 2007 Brazil PS 42 42 90% 45 ±16 30 ±18 Hales 2008 USA PS 15 15 93% 48 ±15 7-65 Smith 2008* USA PS 23 23 70% 50 (24-79) n.s. Traugott 2010 USA PS, multicenter 51 51 80% 50 ±11 6-80 Deandreis 2012 France PS 56 56 76% 50 (18-83) median 21 (10-57) Muñoz Pérez 2013 Spain PS 46 46 80% median 48 (23–78) 28 (10-85) Piccardo 2016 Italy PS 87 87 74% 57 ±13 24 ±13 TOTAL 501 457 *: not included in meta-analysis. age/size: presented as mean ± standard deviation, or provided with range between parentheses, unless otherwise specified. DM: diabetes mellitus. FTC: follicular thyroid carcinoma. FTCOV: FTC, oncocytic variant (Hürthle cell carcinoma). FVPTC: papillary thyroid carcinoma, follicular variant. i: applies to indeterminate thyroid nodules only. MTC: medullary thyroid carcinoma. ni: number of indeterminate thyroid nodules. n.s.: not specified. ntot: total number of thyroid nodules in the study. PS: prospective. PTC: papillary thyroid carcinoma. TN: thyroid nodule. y: years.
RkJQdWJsaXNoZXIy MTk4NDMw